Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors.

Desai J, Gan H, Barrow C, Jameson M, Atkinson V, Haydon A, Millward M, Begbie S, Brown M, Markman B, Patterson W, Hill A, Horvath L, Nagrial A, Richardson G, Jackson C, Friedlander M, Parente P, Tran B, Wang L, Chen Y, Tang Z, Huang W, Wu J, Zeng D, Luo L, Solomon B.

J Clin Oncol. 2020 Mar 17:JCO1902654. doi: 10.1200/JCO.19.02654. [Epub ahead of print]

PMID:
32182156
2.

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.

Fong L, Hotson A, Powderly JD, Sznol M, Heist RS, Choueiri TK, George S, Hughes BGM, Hellmann MD, Shepard DR, Rini BI, Kummar S, Weise AM, Riese MJ, Markman B, Emens LA, Mahadevan D, Luke JJ, Laport G, Brody JD, Hernandez-Aya L, Bonomi P, Goldman JW, Berim L, Renouf DJ, Goodwin RA, Munneke B, Ho PY, Hsieh J, McCaffery I, Kwei L, Willingham SB, Miller RA.

Cancer Discov. 2020 Jan;10(1):40-53. doi: 10.1158/2159-8290.CD-19-0980. Epub 2019 Nov 15.

3.

Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.

Friedlander M, Meniawy T, Markman B, Mileshkin L, Harnett P, Millward M, Lundy J, Freimund A, Norris C, Mu S, Wu J, Paton V, Gao B.

Lancet Oncol. 2019 Sep;20(9):1306-1315. doi: 10.1016/S1470-2045(19)30396-1. Epub 2019 Aug 1.

PMID:
31378459
4.

A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors.

Carducci M, Shaheen M, Markman B, Hurvitz S, Mahadevan D, Kotasek D, Goodman OB Jr, Rasmussen E, Chow V, Juan G, Friberg GR, Gamelin E, Vogl FD, Desai J.

Invest New Drugs. 2018 Dec;36(6):1060-1071. doi: 10.1007/s10637-018-0625-6. Epub 2018 Jul 7.

5.

Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial.

Jonker DJ, Nott L, Yoshino T, Gill S, Shapiro J, Ohtsu A, Zalcberg J, Vickers MM, Wei AC, Gao Y, Tebbutt NC, Markman B, Price T, Esaki T, Koski S, Hitron M, Li W, Li Y, Magoski NM, Li CJ, Simes J, Tu D, O'Callaghan CJ.

Lancet Gastroenterol Hepatol. 2018 Apr;3(4):263-270. doi: 10.1016/S2468-1253(18)30009-8. Epub 2018 Feb 1.

PMID:
29397354
6.

A phase IIa study of HA-irinotecan, formulation of hyaluronic acid and irinotecan targeting CD44 in extensive-stage small cell lung cancer.

Alamgeer M, Neil Watkins D, Banakh I, Kumar B, Gough DJ, Markman B, Ganju V.

Invest New Drugs. 2018 Apr;36(2):288-298. doi: 10.1007/s10637-017-0555-8. Epub 2017 Dec 26.

PMID:
29277856
7.

Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC.

McKeage MJ, Kotasek D, Markman B, Hidalgo M, Millward MJ, Jameson MB, Harris DL, Stagg RJ, Kapoun AM, Xu L, Hughes BGM.

Target Oncol. 2018 Feb;13(1):89-98. doi: 10.1007/s11523-017-0543-0.

PMID:
29188408
8.

Peñaloza-Tranchesi sign secondary to ascending aortic aneurysm and not due to right atrium enlargement.

Santos ECL, Saraiva LR, Markman B, Lordsleem AB, Lima SG, de Souza Vasconcelos M, Dos Santos Filho EC, Holanda AC.

J Electrocardiol. 2017 Nov - Dec;50(6):960-963. doi: 10.1016/j.jelectrocard.2017.07.009. Epub 2017 Jul 12.

PMID:
28807354
9.

Preliminary results of a phase 1A/1B study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb), in patients with advanced hepatocellular carcinoma (HCC).

Yen CJ, Markman B, Chao Y, Hill A, Kang J, Wang L, Li K, Qi Q, Wu Z, Gan H.

Ann Oncol. 2017 Jun;28 Suppl 3:iii54. doi: 10.1093/annonc/mdx261.139. No abstract available.

10.

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.

Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV Jr, Jost L, Keilholz U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y.

ESMO Open. 2016 Sep 29;1(5):e000097. eCollection 2016. Review.

11.

Guideline for stable coronary artery disease.

Cesar LA, Ferreira JF, Armaganijan D, Gowdak LH, Mansur AP, Bodanese LC, Sposito A, Sousa AC, Chaves AJ, Markman B, Caramelli B, Vianna CB, Oliveira CC, Meneghetti C, Albuquerque DC, Stefanini E, Nagib E, Pinto IM, Castro I, Saad JA, Schneider JC, Tsutsui JM, Carneiro JK, Torres K, Piegas LS, Dallan LA, Lisboa LA, Sampaio MF, Moretti MA, Lopes NH, Coelho OR, Lemos P, Santos RD, Botelho R, Staico R, Meneghello R, Montenegro ST, Vaz VD; Sociedade Brasileira de Cardiologia.

Arq Bras Cardiol. 2014 Aug;103(2 Suppl 2):1-56. English, Portuguese. No abstract available.

12.

Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.

Papadopoulos KP, Tabernero J, Markman B, Patnaik A, Tolcher AW, Baselga J, Shi W, Egile C, Ruiz-Soto R, Laird AD, Miles D, Lorusso PM.

Clin Cancer Res. 2014 May 1;20(9):2445-56. doi: 10.1158/1078-0432.CCR-13-2403. Epub 2014 Feb 28.

13.

Nonimaging optics in luminescent solar concentration.

Markman BD, Ranade RR, Giebink NC.

Opt Express. 2012 Sep 10;20 Suppl 5:A622-9. doi: 10.1364/OE.20.00A622.

PMID:
23037529
14.

PI3K pathway inhibitors: better not left alone.

Markman B, Tao JJ, Scaltriti M.

Curr Pharm Des. 2013;19(5):895-906. Review.

PMID:
22973958
15.

Application of monoclonal antibodies as cancer therapy in solid tumors.

Dienstmann R, Markman B, Tabernero J.

Curr Clin Pharmacol. 2012 May;7(2):137-45. Review.

PMID:
22432839
16.

Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors.

Markman B, Tabernero J, Krop I, Shapiro GI, Siu L, Chen LC, Mita M, Melendez Cuero M, Stutvoet S, Birle D, Anak O, Hackl W, Baselga J.

Ann Oncol. 2012 Sep;23(9):2399-408. doi: 10.1093/annonc/mds011. Epub 2012 Feb 22.

17.

Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors.

Paz-Ares LG, Gomez-Roca C, Delord JP, Cervantes A, Markman B, Corral J, Soria JC, Bergé Y, Roda D, Russell-Yarde F, Hollingsworth S, Baselga J, Umana P, Manenti L, Tabernero J.

J Clin Oncol. 2011 Oct 1;29(28):3783-90. doi: 10.1200/JCO.2011.34.8888. Epub 2011 Sep 6.

PMID:
21900113
18.

Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs.

Markman B, Dienstmann R, Tabernero J.

Oncotarget. 2010 Nov;1(7):530-43. Review.

19.

Recent developments in anti-cancer agents targeting PI3K, Akt and mTORC1/2.

Dienstmann R, Rodon J, Markman B, Tabernero J.

Recent Pat Anticancer Drug Discov. 2011 May;6(2):210-36. Review.

PMID:
21294710
20.

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer.

Serra V, Scaltriti M, Prudkin L, Eichhorn PJ, Ibrahim YH, Chandarlapaty S, Markman B, Rodriguez O, Guzman M, Rodriguez S, Gili M, Russillo M, Parra JL, Singh S, Arribas J, Rosen N, Baselga J.

Oncogene. 2011 Jun 2;30(22):2547-57. doi: 10.1038/onc.2010.626. Epub 2011 Jan 31.

21.

Assessment of the quality of simvastatin capsules from compounding pharmacies.

Markman BE, Rosa PC, Koschtschak MR.

Rev Saude Publica. 2010 Dec;44(6):1055-62. English, Portuguese.

22.

EGFR and KRAS in colorectal cancer.

Markman B, Javier Ramos F, Capdevila J, Tabernero J.

Adv Clin Chem. 2010;51:71-119. Review.

PMID:
20857619
23.

New trends in epidermal growth factor receptor-directed monoclonal antibodies.

Markman B, Capdevila J, Elez E, Tabernero J.

Immunotherapy. 2009 Nov;1(6):965-82. doi: 10.2217/imt.09.66. Review.

PMID:
20635913
24.

Integration of anti-epidermal growth factor receptor therapies with cytotoxic chemotherapy.

Serrano C, Markman B, Tabernero J.

Cancer J. 2010 May-Jun;16(3):226-34. doi: 10.1097/PPO.0b013e3181e07670. Review.

PMID:
20526101
25.

Biomarkers in colorectal cancer.

Markman B, Rodríguez-Freixinos V, Tabernero J.

Clin Transl Oncol. 2010 Apr;12(4):261-70. doi: 10.1007/s12094-010-0502-z. Review.

PMID:
20462835
26.

Monoclonal antibodies in solid tumours.

Markman B, Tabernero J.

Curr Clin Pharmacol. 2010 Aug;5(3):160-5. Review.

PMID:
20406174
27.

New approaches and targets in advanced colorectal cancer.

Macarulla T, Capdevila J, Perez-Garcia J, Ramos FJ, Elez ME, Markman B, Ruiz-Echarri M, Tabernero J.

Eur J Cancer. 2009 Sep;45 Suppl 1:79-88. doi: 10.1016/S0959-8049(09)70019-X. No abstract available.

PMID:
19775607
28.

Status of PI3K inhibition and biomarker development in cancer therapeutics.

Markman B, Atzori F, Pérez-García J, Tabernero J, Baselga J.

Ann Oncol. 2010 Apr;21(4):683-91. doi: 10.1093/annonc/mdp347. Epub 2009 Aug 27. Review.

29.

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J.

Cancer Res. 2008 Oct 1;68(19):8022-30. doi: 10.1158/0008-5472.CAN-08-1385.

30.

Antiulcerogenic effects of Campomanesia xanthocarpa.

Markman BE, Bacchi EM, Kato ET.

J Ethnopharmacol. 2004 Sep;94(1):55-7.

PMID:
15261963
31.

Photodynamic therapy in nonsmall cell lung cancer: a systematic review.

Maziak DE, Markman BR, MacKay JA, Evans WK; Cancer Care Ontario Practice Guidelines Initiative Lung Cancer Disease Site Group.

Ann Thorac Surg. 2004 Apr;77(4):1484-91. Review.

PMID:
15063303
32.

Postoperative radiotherapy in stage II or IIIA completely resected non-small cell lung cancer: a systematic review and practice guideline.

Okawara G, Ung YC, Markman BR, Mackay JA, Evans WK; Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care.

Lung Cancer. 2004 Apr;44(1):1-11. Review.

PMID:
15013578
33.

Practice guideline for the role of combination chemotherapy in the initial management of limited-stage small-cell lung cancer.

Laurie SA, Logan D, Markman BR, Mackay JA, Evans WK; Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care.

Lung Cancer. 2004 Feb;43(2):223-40.

PMID:
14739044
34.

Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.

Segal R, Winquist E, Lukka H, Chin JL, Brundage M, Markman BR; Cancer Care Ontario Practice Guidelines Initiative Genitourinary Cancer Disease Site Group.

Can J Urol. 2002 Oct;9(5):1625-33.

PMID:
12431323
35.

The use of conformal radiotherapy and the selection of radiation dose in T1 or T2 low or intermediate risk prostate cancer - a systematic review.

Brundage M, Lukka H, Crook J, Warde P, Bauman G, Catton C, Markman BR, Charette M; Cancer Care Ontario Practice Guidelines Initiative Genitourinary Cancer Disease Site Group.

Radiother Oncol. 2002 Sep;64(3):239-50. Review.

PMID:
12242112
36.

Images in clinical medicine. Spontaneous resolution of a pubic-symphysis diastasis.

Chang D, Markman BS.

N Engl J Med. 2002 Jan 3;346(1):39. No abstract available.

37.

Practice guideline on prophylactic cranial irradiation in small-cell lung cancer.

Kotalik J, Yu E, Markman BR, Evans WK; Cancer Ontario Practice Guidelines Initiative Lung Cancer Disease Site Group.

Int J Radiat Oncol Biol Phys. 2001 Jun 1;50(2):309-16.

PMID:
11380216
38.

Competitive water polo. Upper extremity injuries.

Colville JM, Markman BS.

Clin Sports Med. 1999 Apr;18(2):305-12, vi. Review.

PMID:
10230566
39.

[Patients in health care--easy to read about rights, responsibility, ethics].

Markman B.

Lakartidningen. 1998 Apr 29;95(18):2060. Swedish. No abstract available.

PMID:
9621589
40.

[Good brochure on patient's rights].

Markman B.

Lakartidningen. 1997 Feb 26;94(9):708-9. Swedish. No abstract available.

PMID:
9091737
41.

Symptoms of reactogenicity in field trial of oral cholera vaccine.

Markman B.

Lancet. 1990 Aug 4;336(8710):320. No abstract available.

PMID:
1974013
42.

Anatomy and physiology of adipose tissue.

Markman B.

Clin Plast Surg. 1989 Apr;16(2):235-44. Review.

PMID:
2661105
43.
44.

Anatomy of the subcutaneous tissue of the trunk and lower extremity.

Markman B, Barton FE Jr.

Plast Reconstr Surg. 1987 Aug;80(2):248-54.

PMID:
3602174
45.

Enzyme-linked immunosorbent assay for detection of antibodies to Pseudomonas aeruginosa exoproteins.

Granström M, Wretlind B, Markman B, Pavlovskis OR, Vasil ML.

Eur J Clin Microbiol. 1985 Apr;4(2):197-200.

PMID:
3924608
46.

Immunization against Pseudomonas aeruginosa: the effects of serotype and virulence in mouse protection tests.

Markman B, Fall-Persson M, Salenstedt CR.

J Biol Stand. 1982 Oct;10(4):319-28. No abstract available.

PMID:
6818231
47.

Development of improved cholera vaccine based on subunit toxoid.

Holmgren J, Svennerholm AM, Lönnroth I, Fall-Persson M, Markman B, Lundbeck H.

Nature. 1977 Oct 13;269(5629):602-4. No abstract available.

PMID:
72361
48.

[Polycystic disease of the liver].

Geller AN, Markman BG.

Klin Khir. 1973 Jul;7:51-2. Russian. No abstract available.

PMID:
4731395
49.

The removal by actinomycin D of the effect of endogenous or exogenous animalizing agents in sea urchin development.

Markman B, Runnström J.

Wilhelm Roux Arch Entwickl Mech Org. 1970 Mar;165(1):1-7. doi: 10.1007/BF00576993.

PMID:
28304457
50.

Nuclear changes in the course of development of the sea urchin studied by means of Hale staining.

Immers J, Markman B, Runnström J.

Exp Cell Res. 1967 Sep;47(3):425-42. No abstract available.

PMID:
4167974

Supplemental Content

Loading ...
Support Center